Related Experiment Videos
Insulin glargine (Aventis Pharma).
1Trinity Cottage, Killiney Hill Road, Killiney, County Dublin, Eire. JonesR@iconirl.com
Idrugs : the Investigational Drugs Journal
|July 29, 2005
Summary
Insulin glargine, a novel biosynthetic human insulin analog, has received FDA and EMEA approval for treating types I and II diabetes. Its development and market launch signify a significant advancement in diabetes management.
Area of Science:
- Biotechnology
- Endocrinology
- Pharmacology
Background:
- Insulin glargine is a biosynthetic human insulin analog developed for diabetes mellitus treatment.
- The drug was developed by Aventis Pharma (formerly Hoechst Marion Roussel, HMR).
Purpose of the Study:
- To summarize the development, regulatory approval, and market potential of insulin glargine.
- To highlight its efficacy and safety in treating Type I and Type II diabetes.
Main Methods:
- Review of regulatory filings and approvals in the US (FDA) and Europe (EMEA).
- Analysis of clinical trial phases (Phase I, Phase III) and data submission strategies.
- Examination of market predictions and competitive landscape.
Main Results:
- Insulin glargine (Lantus) received FDA approval in April 2000 for adult patients with Type II diabetes and adult/pediatric patients with Type I diabetes.
- EMEA approval was granted in June 2000 for both Type I and Type II diabetes.
- Phase I trials investigated novel formulations with zinc for extended duration and reduced peak effect.
- The drug is in Phase III trials in Japan.
- Sales forecasts predict significant market penetration and revenue.
Conclusions:
- Insulin glargine represents a significant advancement in basal insulin therapy for diabetes.
- Regulatory approvals in major markets pave the way for widespread clinical use.
- The drug is projected to hold a strong competitive position and achieve substantial sales.